• Eli Lilly Gets Another Shot at FDA Approval for RA Drug biospace
    March 16, 2018
    In April 2017, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Eli Lilly and Company and Incyte Corporation’s baricitinib for moderate-to-severe rheumatoid arthritis (RA).
PharmaSources Customer Service